Cipla Ltd.
- ECONOMY
India Pharma – Yet Another Quarter Of Double-Digit Growth For The IPM: Anand Rathi
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset…
Read More » - ECONOMY
U.S. FDA Flags Quality And Procedural Lapses At Cipla’s Indore Plant
The U.S. drug regulator has flagged quality control and procedural lapses at Cipla Ltd.’s Indore facility in a pre-approval inspection.…
Read More » - ECONOMY
Q1 FY23 Interim Earnings Review – Below Expectations: Motilal Oswal
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset…
Read More » - ECONOMY
Cipla Q1 Review – Strong Margin Recovery: ICICI Securities
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset…
Read More » - ECONOMY
Cipla Q1 Review – Margins Improve Sequentially; Slew Of Launches Ahead: Systematix
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset…
Read More » - ECONOMY
Cipla Q1 Review – Fundamentals On Track: Dolat Capital
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset…
Read More » - ECONOMY
Cipla Q1 Results: Profit Falls But Beats Estimates
Cipla Ltd.’s first-quarter profit fell but beat estimates. The Mumbai-based drugmaker’s net profit was down 4% year-on-year to Rs 686…
Read More » - ECONOMY
Pharma Q1 Preview – Price Erosions In The U.S., Other Markets To Drive Muted Growth In Sales: KRChoksey
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset…
Read More » - ECONOMY
Share Market Live: Sensex, Nifty Erase Gains; I.T. Stocks Decline
Wipro, HCL Tech, Infosys Drag I.T. Index !function(){“use strict”;window.addEventListener(“message”,(function(e){if(void 0!==e.data[“datawrapper-height”]){var t=document.querySelectorAll(“iframe”);for(var a in e.data[“datawrapper-height”])for(var r=0;r<t.length;r++){if(t[r].contentWindow===e.source)t[r].style.height=e.data["datawrapper-height"][a]+"px"}}}))}(); Risk-Reward Less Favourable At Indian…
Read More » - ECONOMY
Pharma, Healthcare Q1 Preview – Expect Tepid Performance With High Base, Elevated Costs: ICICI Securities
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset…
Read More » - ECONOMY
Pharma Q1 Earnings Preview – Recovery In U.S. But High Domestic Base To Weigh: ICICI Direct
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset…
Read More » - ECONOMY
Pharma Q1 Earnings Preview – Cost Pressure Remains: Centrum Broking
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset…
Read More » - ECONOMY
Q3 FY22 Earnings Review – Growth Momentum Continues Unabated: ICICI Direct
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset…
Read More »